Cargando…
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
Despite advances in multimodal treatment, neuroblastoma (NB) is often fatal for children with high-risk disease and many survivors need to cope with long-term side effects from high-dose chemotherapy and radiation. To identify new therapeutic targets, we performed an siRNA screen of the druggable ge...
Autores principales: | Bogen, Dominik, Wei, Jun S., Azorsa, David O., Ormanoglu, Pinar, Buehler, Eugen, Guha, Rajarshi, Keller, Jonathan M., Griner, Lesley A. Mathews, Ferrer, Marc, Song, Young K., Liao, Hongling, Mendoza, Arnulfo, Gryder, Berkley E., Sindri, Sivasish, He, Jianbin, Wen, Xinyu, Zhang, Shile, Shern, John F., Yohe, Marielle E., Taschner-Mandl, Sabine, Shohet, Jason M., Thomas, Craig J., Martin, Scott E., Ambros, Peter F., Khan, Javed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742102/ https://www.ncbi.nlm.nih.gov/pubmed/26497213 |
Ejemplares similares
-
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016) -
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2016) -
Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015) -
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
por: Duffy, David J., et al.
Publicado: (2015) -
Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells
por: Fielitz, Kathrin, et al.
Publicado: (2016)